Rebecca Blank is a Rheumatology/Immunology physician. OpenAlex indexes 27 publications with 4,612 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
324 E 23rd St
New York, NY 100104701
Telephone
212-598-6321Provider last certified this registry record 9 Sept 2021.
Clinical trials
- A Pilot Proof of Concept Study of the Effects of Administration of SCFA in Rheumatoid Arthritis (EASi-RA)
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Fresenius Kabi USA, LLCProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.8%Folate Analog Metabolic Inhibitor30.7%Methotrexate100%Part D≥25 patientsSelective T Cell Costimulation Modulator10.4%Orencia50%Orencia Clickject50%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
25.5%Antidiarrheal microorganisms15.1%Folic Acid100%Part D≥11 patientsCorticosteroid10.4%Prednisone100%Part D≥11 patientsMusculoskeletal
18.7%Nonsteroidal Anti-inflammatory Drug18.7%Diclofenac Sodium70%Naproxen30%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Short-chain fatty acids and their gut microbial pathways distinguish rheumatoid arthritis in discordant monozygotic twins
Annals of the Rheumatic Diseases
2025 - The gut microbiome shapes pharmacology and treatment outcomes for a key anti-inflammatory therapy
bioRxiv (Cold Spring Harbor Laboratory)
2025 - 468 Effects of butyrate supplementation in modulation of gut microbiome and its metabolites in new-onset rheumatoid arthritis
Journal of Clinical and Translational Science
2025
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”